Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apo2L/TRAIL plus rituximab in relapsed follicular CD20-positive B-cell non-Hodgkin lymphoma
ACTRN12608000627358Phase 2Recruiting
- Sponsor
- Genentech
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in follicular lymphoma (FL) comparing Apo2L/TRAIL + rituximab with Rituximab (2 arms). Primary endpoint: Objective response. Started Apr 2006; status: recruiting.
02
Drugs
dulanerminrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ACTRN12608000627358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000627358.